Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus
Authors:
- Leda CoelewijLCLeda Coelewij
- Kirsty E. WaddingtonKWKirsty E. Waddington
- George A. RobinsonGRGeorge A. Robinson
- Thomas McDonnellTMThomas McDonnell
- Filipa FarinhaFFFilipa Farinha
- Junjie PengJPJunjie Peng
- Pierre DönnesPDPierre Dönnes
- Edward SmithESEdward Smith
- Sara CrocaSCSara Croca
- Maura GriffinMGMaura Griffin
Open Access
- 4 February 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (4) , 1446-1458
Abstract
Objective: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease. Standard serum lipid measurements in clinical practice do not predict cardiovascular disease risk in patients with SLE. More detailed analysis of lipoprotein taxonomy could identify better predictors of cardiovascular disease risk in SLE. Approach and Results: Eighty women with SLE and no history of cardiovascular disease underwent carotid and femoral ultrasound scans; 30 had atherosclerosis plaques (patients with SLE with subclinical plaque) and 50 had no plaques (patients with SLE with no subclinical plaque). Serum samples obtained at the time of the scan were analyzed using a lipoprotein-focused metabolomics platform assessing 228 metabolites by nuclear magnetic resonance spectroscopy. Data were analyzed using logistic regression and 5 binary classification models with 10-fold cross validation. Patients with SLE had global changes in complex lipoprotein profiles compared with healthy controls despite having clinical serum lipid levels within normal ranges. In the SLE cohort, univariate logistic regression identified 4 metabolites associated with subclinical plaque; 3 subclasses of VLDL (very low-density lipoprotein; free cholesterol in medium and large VLDL particles and phospholipids in chylomicrons and extremely large VLDL particles) and leucine. Together with age, these metabolites were also within the top features identified by the lasso logistic regression (with and without interactions) and random forest machine learning models. Logistic regression with interactions differentiated between patients with SLE with subclinical plaque and patients with SLE with no subclinical plaque groups with the greatest accuracy (0.800). Notably, free cholesterol in large VLDL particles and age differentiated between patients with SLE with subclinical plaque and patients with SLE with no subclinical plaque in all models. Conclusions: Serum metabolites are promising biomarkers to uncover and predict multimetabolic phenotypes of subclinical atherosclerosis in SLE.Keywords
All Related Versions
This publication has 75 references indexed in Scilit:
- Metabolic Disturbances Associated with Systemic Lupus ErythematosusPLOS ONE, 2012
- Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cellsClinical and Experimental Immunology, 2011
- 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosusLupus, 2011
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular RiskCirculation: Cardiovascular Quality and Outcomes, 2011
- Numerical scoring for the BILAG-2004 indexRheumatology, 2010
- Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosusArthritis & Rheumatism, 2009
- Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritisArthritis Research & Therapy, 2008
- Carotid Atherosclerosis Is a Stronger Predictor of Myocardial Infarction in Women Than in MenStroke, 2007
- Increasing Dietary Leucine Intake Reduces Diet-Induced Obesity and Improves Glucose and Cholesterol Metabolism in Mice via MultimechanismsDiabetes, 2007
- Serum Lipoprotein(a) Level and its Clinical Significance in Patients with Systemic Lupus ErythematosusClinical Rheumatology, 2002